07:00 , May 7, 2007 |  BioCentury  |  Finance

Ebb & Flow

Five executives at MedImmune (MEDI) will be receiving more than $280 million when the $15.6 billion acquisition by AstraZeneca (LSE:AZN; AZN) closes. By comparison, the biotech sector raised a total of $566 million last week,...
07:00 , Aug 4, 2004 |  BC Extra  |  Financial News

Avera raises $48M

Avera (San Diego, Calif.) raised $48 million in a series C round led by Perseus-Soros BioPharmaceutical. Other investors in the autoimmune and neurology company included Schroder Ventures; Aberdare Ventures; BioAsia Investments; H.I.G. Ventures; Montreux Equity;...
08:00 , Mar 15, 2004 |  BioCentury  |  Finance

'A' for effort

'A' for effort Company Raised Date Focus Country Investors Pedigree Biovitrum $85.0 8/1/01 Metabolic Sweden MPM Capital; Nordic Capital; Karolinska Investment Fund; ABN AMRO; Carnegie Asset Management; H&B Capital; Next Gear Spun out of Pharmacia...
08:00 , Mar 9, 2004 |  BC Extra  |  Financial News

Aspreva raises $53 million

Aspreva raised $53 million in a series A round led by Sprout Group. Other investors included InterWest; HBM Partners; Thomas Weisel Healthcare Ventures; BioAsia Investments; and Axiom Venture Partners. Aspreva (Victoria, B.C.) issued an additional...
07:00 , Oct 20, 2003 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Phoenix Pharmacologics Inc. Lexington, Ky. Technology: Recombinant proteins and peptides Disease focus: Cancer, inflammation Clinical status: Phase II Founded: 1996 by Mike Clark and John Bomalaski Corporate partners: TDW University collaborators: None Employees: 18 Funds...
07:00 , Oct 20, 2003 |  BioCentury  |  Finance

Ebb & Flow

Anyone needing another example of the measured approach that IPO investors are taking needn't look much farther than the pricing of two underwritten deals last week: one an IPO and the other a follow-on. While...
07:00 , Oct 13, 2003 |  BioCentury  |  Finance

Ebb & Flow

ID Biomedical's decision to raise $100 million in a bought deal less than a week after pulling a proposed follow-on because it thought the price too low could have left some scratching their heads. The...
07:00 , Jun 23, 2003 |  BC Week In Review  |  Company News

Prestwick board of directors update

Prestwick Pharmaceuticals Inc. , Washington, D.C.   Business: Neurological   Appointed: Edgar Engleman, general partner of BioAsia Investments, as chairman; Robert Flanagan, EVP of Clark Enterprises; Jim Healy, general partner of Sofinnova Ventures; and Joel...
07:00 , Jun 19, 2003 |  BC Extra  |  Financial News

Prestwick raises $15 million

Neurological company Prestwick (Washington, D.C.) raised $15 million in its first venture round, which was led by BioAsia Investments and Sofinnova Ventures. Other investors included Atlas Venture and BA Venture Partners. The company's Xenazine tetrabenazine...
08:00 , Dec 23, 2002 |  BC Week In Review  |  Company News

Angiogenix board of directors update

Angiogenix Inc. , Burlingame, Calif.   Business: Cardiovascular   Appointed: Albert Cha of BioAsia Investments; and Steinar Engelsen of Teknoinvest Management  ...